{"success":true,"data":{"pressRelease":{"id":"145050","rtpr_id":"nBw6RrR1Na-20260916","ticker":"AMSU","exchange":"LSE","all_tickers":["AMSU"],"title":"REG-Qube Research & Technologies LTD Form 8.3","author":"Business Wire","published_at":"2026-09-16T11:54:00.102Z","article_body":"Form 8.3\n\n \n\nFORM 8.3\n\nPUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY\n\nA PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE\n\nRule 8.3 of the Takeover Code (the “Code”)\n\n1. KEY INFORMATION\n (a) Full name of discloser: Qube Research & Technologies Limited \n (b) Owner or controller of interests and short positions disclosed, if   \n different from 1(a): \n \n \n \nThe naming of nominee or vehicle companies is insufficient. For a trust, the \n trustee(s), settlor and beneficiaries must be named. \n (c) Name of offeror/offeree in relation to whose relevant securities this form Advanced Medical Solutions Group plc \n relates: \n \n \n \nUse a separate form for each offeror/offeree \n (d) If an exempt fund manager connected with an offeror/offeree, state this   \n and specify identity of offeror/offeree: \n (e) Date position held/dealing undertaken: 15-09-2026 \n \n \n \nFor an opening position disclosure, state the latest practicable date prior to \n the disclosure \n (f) In addition to the company in 1(c) above, is the discloser making N/A \n disclosures in respect of any other party to the offer? \n \n \n \n  \n \nIf it is a cash offer or possible cash offer, state “N/A” \n\n\n2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE\n\nIf there are positions or rights to subscribe to disclose in more than one\nclass of relevant securities of the offeror or offeree named in 1(c), copy\ntable 2(a) or (b) (as appropriate) for each additional class of relevant\nsecurity.\n\n(a) Interests and short positions in the relevant securities of the offeror or\nofferee to which the disclosure relates following the dealing (if any)\n Class of relevant security: 5p ordinary \n   Interests Short positions \n \n \n \n  \n Number % Number % \n (1) Relevant securities owned and/or controlled: 0 0.00 0 0.00 \n (2) Cash-settled derivatives: 6,931,902 3.13 50,271 0.02 \n (3) Stock-settled derivatives (including options) and agreements to 0 0.00 0 0.00 \n purchase/sell: \n   6,931,902 3.13 50,271 0.02 \n \n \n \nTOTAL: \n\n\nAll interests and all short positions should be disclosed.\n\nDetails of any open stock-settled derivative positions (including traded\noptions), or agreements to purchase or sell relevant securities, should be\ngiven on a Supplemental Form 8 (Open Positions).\n\n(b) Rights to subscribe for new securities (including directors’ and other\nemployee options)\n Class of relevant security in relation to which subscription right exists: 0 \n Details, including nature of the rights concerned and relevant percentages: 0 \n\n\n3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE\n\nWhere there have been dealings in more than one class of relevant securities\nof the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as\nappropriate) for each additional class of relevant security dealt in.\n\nThe currency of all prices and other monetary amounts should be stated.\n\n(a) Purchases and sales\n Class of relevant security Purchase/sale Number of securities Price per unit (CCY0) \n \n \n \n  \n\n\n(b) Cash-settled derivative transactions\n Class of relevant security Product description Nature of dealing Number of securities Exercise price per unit (GBp) \n \n \n \n \ne.g. call option \ne.g. opening/closing a long/short position, increasing/reducing a long/short \n position \n 5p ordinary equity swap decreasing a short position 412 281.00 \n 5p ordinary equity swap decreasing a short position 21 281.50 \n 5p ordinary equity swap increasing a long position 8101 281.00 \n\n\n(c) Stock-settled derivative transactions (including options)\n\n(i) Writing, selling, purchasing or varying\n Class of relevant security Product description e.g. call option Writing, purchasing, selling, varying etc. Number of securities to which option relates Exercise price per unit (CCY0) Type Expiry date Option money paid/ received per unit \n \n \n \n \ne.g. American, European etc. \n(CCY0) \n\n\n(ii) Exercise\n Class of relevant security Product description Exercising/ exercised against Number of securities Exercise price per unit \n \n \n \ne.g. call option \n 0 0 0 0   \n \n \n \n0 \n\n\n(d) Other dealings (including subscribing for new securities)\n Class of relevant security Nature of dealing Details Price per unit (if applicable) \n \n \n \ne.g. subscription, conversion \n 0   0 0 \n \n \n \n0 \n\n\n4. OTHER INFORMATION\n\n(a) Indemnity and other dealing arrangements\n Details of any indemnity or option arrangement, or any agreement or \n understanding, formal or informal, relating to relevant securities which may \n be an inducement to deal or refrain from dealing entered into by the person \n making the disclosure and any party to the offer or any person acting in \n concert with a party to the offer: \n \n \n \nIrrevocable commitments and letters of intent should not be included. If there \n are no such agreements, arrangements or understandings, state “none” \n   \n \n \n \nNone \n \n \n \n  \n\n\n(b) Agreements, arrangements or understandings relating to options or\nderivatives\n Details of any agreement, arrangement or understanding, formal or informal, \n between the person making the disclosure and any other person relating to: \n \n \n \n(i) the voting rights of any relevant securities under any option; or \n \n \n \n(ii) the voting rights or future acquisition or disposal of any relevant \n securities to which any derivative is referenced: \n \n \n \nIf there are no such agreements, arrangements or understandings, state \n “none” \n   \n \n \n \nNone \n \n \n \n  \n\n\n(c) Attachments\n Is a Supplemental Form 8 (Open Positions) attached? NO \n\n Date of disclosure: 16-09-2026 \n Contact name: Janice Falcao \n Telephone number: 00442033140679 \n\n\nPublic disclosures under Rule 8 of the Code must be made to a Regulatory\nInformation Service.\n\nThe Panel’s Market Surveillance Unit is available for consultation in\nrelation to the Code’s disclosure requirements on +44 (0)20 7638 0129. The\nCode can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.thetakeoverpanel.org.uk%2F&esheet=54605280&newsitemid=20260916998868&lan=en-US&anchor=www.thetakeoverpanel.org.uk&index=1&md5=7812150c1be39228b6744cd40a8c64af)\n.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260916998868/en/\n(https://www.businesswire.com/news/home/20260916998868/en/)\n\nQube Research & Technologies LTD\n\n\nCopyright Business Wire 2026","article_body_html":"","raw_payload":{"data":{"id":"nBw6RrR1Na-20260916","title":"REG-Qube Research & Technologies LTD Form 8.3","author":"Business Wire","ticker":"AMSU","created":"2026-09-16T11:54:00.102Z","tickers":["AMSU"],"exchange":"LSE","article_body":"Form 8.3\n\n \n\nFORM 8.3\n\nPUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY\n\nA PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE\n\nRule 8.3 of the Takeover Code (the “Code”)\n\n1. KEY INFORMATION\n (a) Full name of discloser: Qube Research & Technologies Limited \n (b) Owner or controller of interests and short positions disclosed, if   \n different from 1(a): \n \n \n \nThe naming of nominee or vehicle companies is insufficient. For a trust, the \n trustee(s), settlor and beneficiaries must be named. \n (c) Name of offeror/offeree in relation to whose relevant securities this form Advanced Medical Solutions Group plc \n relates: \n \n \n \nUse a separate form for each offeror/offeree \n (d) If an exempt fund manager connected with an offeror/offeree, state this   \n and specify identity of offeror/offeree: \n (e) Date position held/dealing undertaken: 15-09-2026 \n \n \n \nFor an opening position disclosure, state the latest practicable date prior to \n the disclosure \n (f) In addition to the company in 1(c) above, is the discloser making N/A \n disclosures in respect of any other party to the offer? \n \n \n \n  \n \nIf it is a cash offer or possible cash offer, state “N/A” \n\n\n2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE\n\nIf there are positions or rights to subscribe to disclose in more than one\nclass of relevant securities of the offeror or offeree named in 1(c), copy\ntable 2(a) or (b) (as appropriate) for each additional class of relevant\nsecurity.\n\n(a) Interests and short positions in the relevant securities of the offeror or\nofferee to which the disclosure relates following the dealing (if any)\n Class of relevant security: 5p ordinary \n   Interests Short positions \n \n \n \n  \n Number % Number % \n (1) Relevant securities owned and/or controlled: 0 0.00 0 0.00 \n (2) Cash-settled derivatives: 6,931,902 3.13 50,271 0.02 \n (3) Stock-settled derivatives (including options) and agreements to 0 0.00 0 0.00 \n purchase/sell: \n   6,931,902 3.13 50,271 0.02 \n \n \n \nTOTAL: \n\n\nAll interests and all short positions should be disclosed.\n\nDetails of any open stock-settled derivative positions (including traded\noptions), or agreements to purchase or sell relevant securities, should be\ngiven on a Supplemental Form 8 (Open Positions).\n\n(b) Rights to subscribe for new securities (including directors’ and other\nemployee options)\n Class of relevant security in relation to which subscription right exists: 0 \n Details, including nature of the rights concerned and relevant percentages: 0 \n\n\n3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE\n\nWhere there have been dealings in more than one class of relevant securities\nof the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as\nappropriate) for each additional class of relevant security dealt in.\n\nThe currency of all prices and other monetary amounts should be stated.\n\n(a) Purchases and sales\n Class of relevant security Purchase/sale Number of securities Price per unit (CCY0) \n \n \n \n  \n\n\n(b) Cash-settled derivative transactions\n Class of relevant security Product description Nature of dealing Number of securities Exercise price per unit (GBp) \n \n \n \n \ne.g. call option \ne.g. opening/closing a long/short position, increasing/reducing a long/short \n position \n 5p ordinary equity swap decreasing a short position 412 281.00 \n 5p ordinary equity swap decreasing a short position 21 281.50 \n 5p ordinary equity swap increasing a long position 8101 281.00 \n\n\n(c) Stock-settled derivative transactions (including options)\n\n(i) Writing, selling, purchasing or varying\n Class of relevant security Product description e.g. call option Writing, purchasing, selling, varying etc. Number of securities to which option relates Exercise price per unit (CCY0) Type Expiry date Option money paid/ received per unit \n \n \n \n \ne.g. American, European etc. \n(CCY0) \n\n\n(ii) Exercise\n Class of relevant security Product description Exercising/ exercised against Number of securities Exercise price per unit \n \n \n \ne.g. call option \n 0 0 0 0   \n \n \n \n0 \n\n\n(d) Other dealings (including subscribing for new securities)\n Class of relevant security Nature of dealing Details Price per unit (if applicable) \n \n \n \ne.g. subscription, conversion \n 0   0 0 \n \n \n \n0 \n\n\n4. OTHER INFORMATION\n\n(a) Indemnity and other dealing arrangements\n Details of any indemnity or option arrangement, or any agreement or \n understanding, formal or informal, relating to relevant securities which may \n be an inducement to deal or refrain from dealing entered into by the person \n making the disclosure and any party to the offer or any person acting in \n concert with a party to the offer: \n \n \n \nIrrevocable commitments and letters of intent should not be included. If there \n are no such agreements, arrangements or understandings, state “none” \n   \n \n \n \nNone \n \n \n \n  \n\n\n(b) Agreements, arrangements or understandings relating to options or\nderivatives\n Details of any agreement, arrangement or understanding, formal or informal, \n between the person making the disclosure and any other person relating to: \n \n \n \n(i) the voting rights of any relevant securities under any option; or \n \n \n \n(ii) the voting rights or future acquisition or disposal of any relevant \n securities to which any derivative is referenced: \n \n \n \nIf there are no such agreements, arrangements or understandings, state \n “none” \n   \n \n \n \nNone \n \n \n \n  \n\n\n(c) Attachments\n Is a Supplemental Form 8 (Open Positions) attached? NO \n\n Date of disclosure: 16-09-2026 \n Contact name: Janice Falcao \n Telephone number: 00442033140679 \n\n\nPublic disclosures under Rule 8 of the Code must be made to a Regulatory\nInformation Service.\n\nThe Panel’s Market Surveillance Unit is available for consultation in\nrelation to the Code’s disclosure requirements on +44 (0)20 7638 0129. The\nCode can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.thetakeoverpanel.org.uk%2F&esheet=54605280&newsitemid=20260916998868&lan=en-US&anchor=www.thetakeoverpanel.org.uk&index=1&md5=7812150c1be39228b6744cd40a8c64af)\n.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260916998868/en/\n(https://www.businesswire.com/news/home/20260916998868/en/)\n\nQube Research & Technologies LTD\n\n\nCopyright Business Wire 2026"},"type":"article","timestamp":"2026-09-16T11:54:00.156329338Z","server_sent_at_ms":1789559640156},"received_at":"2026-09-16T11:54:00.215Z","source_url":"https://www.businesswire.com/news/home/20260916998868/en/"},"analysis":{"id":"133882","press_release_id":"145050","analysis_json":{"industry":{"label":"Health Care Equipment & Supplies","sector":"Health Care"},"redFlags":[],"eventType":"regulatory","narrative":"Qube Research & Technologies Limited filed a Rule 8.3 Takeover Code position disclosure relating to Advanced Medical Solutions Group plc, with positions held as of 15 September 2026.\n\nQube reported a long position of 6,931,902 shares (3.13%) entirely via cash-settled derivatives, against a short position of 50,271 shares (0.02%), and no outright ownership of the underlying shares.\n\nIts disclosed dealings were modestly net long: equity swaps cut short positions by 433 shares at 281.00-281.50 GBp and added 8,101 shares to the long side at 281.00 GBp.\n\nThe form states there are no indemnity, option, or voting arrangements and no Supplemental Form 8 attached — routine disclosure plumbing, though its filing under Rule 8.3 confirms Advanced Medical Solutions sits in an active Takeover Code offer period.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Qube's 8.3 shows a 3.13% synthetic net long in AMSU during the offer period — merge-arb flow color only, no new deal news."},"keyFigures":{"customDimensions":{"position_date":"15-09-2026","short_position_pct":"0.02%","outright_shares_owned":0,"short_position_shares":50271,"swap_long_increased_shares":8101,"cash_settled_derivative_long_pct":"3.13%","cash_settled_derivative_long_shares":6931902}},"namedEntities":{"people":[{"name":"Janice Falcao","role":"disclosure contact for Qube Research & Technologies Limited"}],"products":[],"companies":[{"name":"Qube Research & Technologies Limited","relationship":"discloser / position holder filing the Form 8.3"},{"name":"Advanced Medical Solutions Group plc","relationship":"offeree (subject company of the Takeover Code disclosure)"}],"dollarAmounts":[{"amount":"281.00","context":"equity swap price per unit (GBp) on decreased short position of 412 shares and increased long position of 8,101 shares"},{"amount":"281.50","context":"equity swap price per unit (GBp) on decreased short position of 21 shares"}]},"materialImpact":{"score":2,"reasoning":"Routine UK Takeover Code Rule 8.3 position disclosure by quant fund Qube Research & Technologies; no new corporate action. The only incremental signal is Qube's 3.13% cash-settled derivative long in the offeree plus modest net-long equity swap dealings during an active offer period."},"tickerRelevance":{"others":[],"primary":"AMSU"},"globalImportance":8,"audienceRelevance":8,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small/mid-cap UK-listed medtech","eventGravity":"routine Takeover Code Rule 8.3 position disclosure","disclosureType":"Form 8.3 by third-party fund (Qube)","issuerAuthored":false,"retailFavoriteBoost":false}},"event_type":"regulatory","event_type_secondary":null,"sentiment":"neutral","material_impact_score":2,"narrative":"Qube Research & Technologies Limited filed a Rule 8.3 Takeover Code position disclosure relating to Advanced Medical Solutions Group plc, with positions held as of 15 September 2026.\n\nQube reported a long position of 6,931,902 shares (3.13%) entirely via cash-settled derivatives, against a short position of 50,271 shares (0.02%), and no outright ownership of the underlying shares.\n\nIts disclosed dealings were modestly net long: equity swaps cut short positions by 433 shares at 281.00-281.50 GBp and added 8,101 shares to the long side at 281.00 GBp.\n\nThe form states there are no indemnity, option, or voting arrangements and no Supplemental Form 8 attached — routine disclosure plumbing, though its filing under Rule 8.3 confirms Advanced Medical Solutions sits in an active Takeover Code offer period.","key_figures":{"customDimensions":{"position_date":"15-09-2026","short_position_pct":"0.02%","outright_shares_owned":0,"short_position_shares":50271,"swap_long_increased_shares":8101,"cash_settled_derivative_long_pct":"3.13%","cash_settled_derivative_long_shares":6931902}},"named_entities":{"people":[{"name":"Janice Falcao","role":"disclosure contact for Qube Research & Technologies Limited"}],"products":[],"companies":[{"name":"Qube Research & Technologies Limited","relationship":"discloser / position holder filing the Form 8.3"},{"name":"Advanced Medical Solutions Group plc","relationship":"offeree (subject company of the Takeover Code disclosure)"}],"dollarAmounts":[{"amount":"281.00","context":"equity swap price per unit (GBp) on decreased short position of 412 shares and increased long position of 8,101 shares"},{"amount":"281.50","context":"equity swap price per unit (GBp) on decreased short position of 21 shares"}]},"model_name":"glm-5.3-flash","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-16T11:54:46.161Z","global_importance":8,"audience_relevance":8,"importance_components":{"tickerTier":"small/mid-cap UK-listed medtech","eventGravity":"routine Takeover Code Rule 8.3 position disclosure","disclosureType":"Form 8.3 by third-party fund (Qube)","issuerAuthored":false,"retailFavoriteBoost":false}},"durationMs":45932,"modelName":"glm-5.3-flash"}}